Clin2
NCT06934200Worth exploringRecruiting

Xolair for food allergy in people with high IgE

Food Hypersensitivity

Treatments studied

Part of Immune system & allergy clinical trials.

This study tests if omalizumab (Xolair), an injectable medicine that blocks allergy antibodies, can help people with food allergies tolerate small amounts of their trigger foods. It's for people with high total IgE levels who were not eligible for a related study.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
32 people
Ages
1 year to 55 years
Study type
Interventional

Who can take part

  • You are between 1 and 55 years old.
  • You have a clear allergy to at least one of these foods: peanut, cashew, walnut, egg, milk, or wheat.
  • You have a history of reacting to a very small amount of that food during a doctor-supervised food challenge.
  • You have high total IgE levels (a type of allergy antibody) that would have prevented you from joining a similar study.
  • You do not have severe asthma, cancer, or a history of serious allergic reactions requiring breathing help.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT03835767Recruiting· Phase 2
Predicting food allergy from blood IgE levels in eczema patients

This study looks for blood test patterns that may predict whether a child with eczema (atopic dermatitis) is likely to have a food allergy. If you join, you may do supervised oral food challenges with a placebo and the suspected foods to see what triggers symptoms.

Bethesda, Maryland
NCT05332067Recruiting· Phase 2
Omalizumab to prevent future asthma flare-ups before they start

This trial studies whether starting omalizumab before asthma flare-ups begin can reduce how often children get worsening asthma that needs strong steroid medicine. It is for children with persistent asthma who have signs of allergic/asthma triggers and recent flare-up history.

Washington D.C., District of Columbia
NCT06943534Recruiting· Phase 2
Omalizumab for severe food allergies: weight-based dosing study

This trial tests if omalizumab (a drug that blocks allergy reactions) can help people with multiple food allergies. You might qualify if you have severe allergies to at least two foods like peanut, tree nuts, egg, or milk.

Boston, Massachusetts
NCT06618963Recruiting· Phase 4
Omalizumab for food allergy skin effects

This trial tests if omalizumab (Xolair) can improve skin reactions in people with food allergies. It may help reduce allergic symptoms triggered by foods like peanut, egg, or milk.

Denver, Colorado
NCT07059091Recruiting· Phase 2
Omalizumab for COPD with allergies

This trial tests if omalizumab, an allergy medication, can help people with COPD who have allergies to common indoor triggers like cat, dog, mouse, cockroach, or dust mite. It aims to reduce flare-ups and improve breathing.

Birmingham, Alabama
NCT07073404Not yet recruiting
Omalizumab for plant-food allergy from LTP or profilin

This trial tests a drug called omalizumab for people with plant-food allergies caused by two specific proteins: LTP (found in peach skin) and profilin (found in melon). The goal is to see if the drug can help reduce allergic reactions.

Hear when a new Food Hypersensitivity trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.